Inosine

Researchers are currently enrolling people with ALS in a research study which is evaluating the safety of Inosine, a supplement that is used to raise blood levels of uric acid. Your participation in this study would be at least 27 weeks. The purpose of the research study is to determine whether inosine is safe and tolerable for patients with Amyotrophic Lateral Sclerosis (ALS). While taking the study drug, participants will be asked to complete several tests and utilize a mobile application to collect information on tasks. From this study, the researchers hope to learn more about ALS and its treatment. The study will take participants 27 weeks to complete**.** Participants must be at least 18 years of age.

Principal Investigator: Katharine Nicholson, MD

Contact:
Jianing Liu
617-726-1880
jliu45@partners.org

Brainstorm

The purpose of the study is to evaluate the safety and efficacy of transplanting self-derived mesenchymal stem cells secreting neurotrophic factors (MSC-NTF) into the cerebrospinal fluid in patients with ALS. The cells are derived from your own bone marrow and administered into your cerebrospinal fluid three times (once every 8 weeks for 16 weeks). Participation in this study will last approximately 11 months.

Principal Investigator: James Berry, MD, MPH

Contact:
Taylor Mezoian
617-643-0312
tmezoian@mgh.harvard.edu

Actemra

The purpose of this study is to evaluate whether Actemra (Tocilizumab) is safe, tolerable and effective in people with ALS. Tocilizumab hopes to reduce inflammation by impeding both classical and trans-signaling IL-6 pathways that could be related to the progression of ALS.

Participants must be between 18 and 75 years old, have received a possible, probable or confirmed ALS diagnosis, and be able to comply with study procedures. The study team will review a complete list of the trial's inclusion and exclusion criteria with potential subjects during a screening visit, to ensure it will be safe for you to enroll. Participation in this study requires up to 8 study visits to MGH over 4 months.

Principal Investigator: Suma Babu, MD

Contact:
Harli Weber
617-643-5376
hweber1@mgh.harvard.edu

For more information about any of these trials, please contact the listed study coordinator or one of our research nurses:

Judi Carey, R.N., (617) 724-8995

jcarey8@partners.org

Sarah Luppino, R.N., (617) 724-3380

Katie Campbell, R.N., (617) 643-6249

Jen Scalia, R.N., (617) 726-0316

Danica Sanders, R.N., (617) 643-6249

Taylor Stirrat, R.N., (617) 726-5059

Updated: March 2018

MASSACHUSETTS GENERAL HOSPITAL
NEUROLOGICAL CLINICAL RESEARCH INSTITUTE

NCRI

Interventional Studies Currently Recruiting

For more information, visit:

http://www.massgeneral.org/als/

http://www.alsconsortium.org

Ibudilast

This study is recruiting participants with the following criteria:

1) Adults with Amyotrophic Lateral Sclerosis (ALS) to receive study drug and undergo several study procedures
2) Adults willing to undergo MRI/PET scans at two time points to look at inflammation in the brain. These participants should have no metal or electrically powered implants in their body, and should be able to lay flat for at least 90 minutes.

The purpose of the research study is to determine whether the drug MN-166 (Ibudilast) is safe and tolerable for patients with ALS. This study will also examine whether MN-166 changes blood and brain biomarkers of inflammation in ALS. Participation in the study will last for approximately 40 weeks and will require 6 in-person visits, and 8 telephonic follow-up visits.

Principal Investigator: Nazem Atassi, MD, MMSc

Contact:
Catherine Cebulla
617-643-6252
ccebulla@mgh.harvard.edu



Genentech

The purpose of the research study is to determine whether the drug GDC-0134 is safe and tolerable for patients with ALS. This study will also look at the amount of study drug in your blood after different doses are taken. Participation in this study will last approximately three to five months. Participants may have the opportunity to participate in more than one dosing period. Each dosing period will require one four-night stay in the hospital during GDC-0134 dosing, and a follow up visit at one week and two weeks post-dosing. Participants must be at least 18 years of age, and able to comply with study procedures. We will review a complete list of the study's inclusion and exclusion criteria with you during a screening visit, to ensure it will be safe for you to enroll.

Principal Investigator: Nazem Atassi, MD, MMSc

Contact:
Brixhilda Dedi
617-726-4284
bdedi@mgh.harvard.edu

Biogen SOD1

We are doing this research study to find out about the safety and tolerability of the study drug BIIB067. This study is recruiting SOD1-ALS patients with a forced vital capacity greater than or equal to 50% of predicted value. Participation will last for approximately 31 weeks and will include an overnight stay at MGH in addition to in-person visits. There are additional inclusion/exclusion criteria that the study team will review with you in more detail if you are interested in participating.

Principal Investigator: Nazem Atassi, MD, MMSc

Contact:
Jacob Dewitz
617-726-0563
jdewitz@mgh.harvard.edu

Centaur (Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA))

This research study is being done to find out if AMX0035 can help with Amyotrophic Lateral Sclerosis (ALS). We also want to find out if AMX 0035 is safe to take without causing too many side effects.

AMX0035, a combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), is not approved by the US Food and Drug Association (FDA). This means that AMX0035 can only be used in research studies. This is the first use of the combination drug AMX0035 in humans. However, the individual components of the drug, PB and TUDCA, have been studied in small clinical trials of patients with ALS.

This research study will compare AMX0035 to placebo. Participants will receive study drug for a total of 24 weeks, followed by a telephone call about 30 days from the final study visit. During this time, we will ask participants to make up to seven study visits to the clinic and four telephone calls. Overall participants may be in the research study for about 8 months.

Principal Investigator: James Berry, MD, MPH

Contact:
Aileen Shaughnessy
617-724-9196
anshaughnessy@mgh.harvard.edu

Cross-Sectional Analysis of Biofluid Biomarkers (CABB)
+Healthy Volunteers

The main purpose of this study is to collect blood from people with ALS and related motor neuron diseases (MND) and those without ALS or MND (controls). These samples are used to understand and develop new therapies for ALS and will be shared with researchers across the globe performing promising research. Participants must be at least 18 years of age. The study only requires one-in person visit during which medical history and clinical information will be gathered and blood will be drawn. Urine collection and cerebrospinal fluid collection via spinal tap are optional. People with ALS may also participate in follow-up visits 6 and 12 months later, which may be done in-person, over telephone or by collecting information from medical records.

Principal Investigator: James Berry, MD, MPH

Contact:
Connor Freeh
617-726-4282
cfreeh@partners.org

Speech Motor Impairment in ALS

The Speech and Feeding Disorders Lab at MGH Institute of Health Professions is interested in studying the movements the face and mouth during speech, chewing and swallowing in persons diagnosed with ALS and healthy volunteers. You will be asked to fill out a health questionnaire as well as to repeat various sounds and sentences while the movements of your face and mouth are recorded. This research aims to help improve the diagnosis and treatments of ALS, and to help develop new technologies that will help improve communication for people with speech impairments.

Contact:
Speech and Feeding Disorders Lab
617-724-6347
speechfeedinglab@mghihp.edu

For more information about any of these trials, please contact the listed study coordinator or one of our research nurses:

Judi Carey, R.N., (617) 724-8995

jcarey8@partners.org

Sarah Luppino, R.N., (617) 724-3380

Katie Campbell, R.N., (617) 643-6249

Jen Scalia, R.N., (617) 726-0316

Danica Sanders, R.N., (617) 643-6249

Taylor Stirrat, R.N., (617) 726-5059

Updated: March 2018

MASSACHUSETTS GENERAL HOSPITAL
NEUROLOGICAL CLINICAL RESEARCH INSTITUTE

NCRI

Biofluid Biomarker & Observational Studies Currently Recruiting

For more information, visit:

http://www.massgeneral.org/als/

http://www.alsconsortium.org

SOD1 Kinetics
+Healthy Volunteers

The purpose of this study is to find out how long the SOD1 protein stays in cerebrospinal fluid (CSF). The SOD1 protein is known to cause some forms of familial Amyotrophic Lateral Sclerosis (ALS). This study is recruiting adults with SOD1-confirmed Amyotrophic Lateral Sclerosis (ALS), Sporadic ALS (not caused by SOD1 gene), SOD1-positive asymptomatic gene carriers, and healthy adults with no medical history of neurological disease.

This study involves drinking a special leucine-labeled beverage for 10 days, which will be provided by the study team. Participation in this study will last approximately 4 months and requires 6 visits to MGH. Four of these visits will involve a lumbar puncture (LP).

Participants must be 18 years of age, able to comply with study procedures, and be medically safe to undergo a lumbar puncture (LP).

Principal Investigator: Katharine Nicholson, MD

Contact:
Jacob Dewitz
617-726-0563
jdewitz@mgh.harvard.edu

Smartphone App for ALS

This study is recruiting adults with ALS who are smartphone users and are able to download and use a smartphone application. The study asks each participant to use the smartphone application for a few minutes every day by answering a questionnaire/survey, recording your voice and/or performing an on-screen exercise. The purpose of the research study is to determine how helpful a smartphone application would be in collecting research data and to learn more about disease progression.

Individuals will be in the study for about 3 months and will have the option to extend their participation by another 3 months. Participants must be at least 18 years of age.

Principal Investigator: James Berry, MD, MPH

Contact:
Mehdi Husain
617-643-2499
mhusain@mgh.harvard.edu

Skin Biopsy/Stem Cells for Research in MND
+Healthy Volunteers

Neurodegenerative diseases are diseases in which nerve cells of the brain and spinal cord die. There is a need to understand the cause of these diseases and to develop treatments. Recent advancements in stem cell technology have allowed us to create a person's own nerve cells by taking a skin biopsy or blood sample. This study wants to use this new technology to make models for neurodegenerative diseases. We hope this will give us a better understanding of the diseases, enable us to use the cells for drug screening, and in the future, develop treatments.

Principal Investigator: James Berry, MD, MPH

Contact:
Connor Freeh
617-726-4282
cfreeh@partners.org

Answer ALS
+Healthy Volunteers

Answer ALS is a research study that is helping to create the largest-ever collection of stem cell lines derived from the blood of people with ALS. The collection of cells will be linked to detailed clinical information and a repository of biospecimens. The cell lines and clinical data will be studied in laboratories from across the country that have partnered for this project. Data from these labs will be analyzed individually and together using "big data" analysis techniques to demonstrate why and how motor neurons are affected by ALS, to identify biologically unique subgroups of people with ALS, and to search for new targets for drug therapy.

Participants must be at least 18 years of age, and able to follow study tasks. Participants will be asked to come to MGH approximately every 3 months for 1 year, and will be followed by telephone thereafter for as long as they are willing.

Principal Investigator: James Berry, MD, MPH

Contact:
Brixhilda Dedi
617-726-4284
bdedi@mgh.harvard.edu

Neuroinflammation (PBR28) Imaging Study

This study is being conducted to learn more about inflammation in the brain of people with ALS and PLS. Our study will examine whether particular cells called microglia are hyperactive in the nervous system of people with ALS or PLS using Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET). This information could help improve the diagnosis and development of treatments for other patients with ALS or PLS in the future.

Study participation involves up to six hospital visits over the course of 24 months, plus brief phone calls every three months for up to 48 months after enrollment. Procedures include a combined MRI/PET scan, clinical measures such as breathing tests, and questionnaires. Participants will be reimbursed for parking and receive compensation of $150 for completing the baseline MRI/PET scan. Participants may elect to complete four additional scans, compensated at $150 each, during their follow up visits at the hospital.

Principal Investigator: Nazem Atassi, MD, MMSc

Contact:
Catherine Cebulla
617-643-6252
ccebulla@mgh.harvard.edu



For more information about any of these trials, please contact the listed study coordinator or one of our research nurses:

Judi Carey, R.N., (617) 724-8995

jcarey8@partners.org

Sarah Luppino, R.N., (617) 724-3380

Katie Campbell, R.N., (617) 643-6249

Jen Scalia, R.N., (617) 726-0316

Danica Sanders, R.N., (617) 643-6249

Taylor Stirrat, R.N., (617) 726-5059

Updated: March 2018

MASSACHUSETTS GENERAL HOSPITAL
NEUROLOGICAL CLINICAL RESEARCH INSTITUTE

NCRI

Imaging Biomarker Studies Currently Recruiting

For more information visit:

http://www.massgeneral.org/als/

http://www.alsconsortium.org

SPINE-ALS

We are doing this research to learn more about changes in the spinal cord and brain in ALS. "Microglia" are a type of immune cell that we are particularly interested in. We would like to find out if microglia are activated in the spinal cord and brain of individuals with ALS. Special imaging techniques are now available to test for changes in microglia. Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) are two tests that allow us to take pictures and "look inside" the body without surgery. MR-PET scanners use both MRI and PET tests at the same time. The MR-PET scanner may give clearer images and more information about the inside of the body.

If you choose to take part in this study you may have 2 visits at MGH, up to 3 months apart. We will pay you $150 for completion of the spinal cord MR-PET scan. If you choose to participate in the optional brain MR-PET scan you will be paid an additional $50 for completion.

Principal Investigator: Nazem Atassi, MD, MMSc

Contact:
Beverly Reynolds
617-643-2522
bvreynolds@mgh.harvard.edu



TRACK-ALS

+Healthy Volunteers

TRACK-ALS is a multicenter, longitudinal study which aims to identify imaging and biofluid biomarkers in people with ALS to expand the understanding of disease pathology and progression. By identifying changes that occur in the blood, brain, and cerebrospinal fluid (CSF) of individuals with ALS, this pilot project has the potential to inform both diagnostic measures and drug development. Participation in the study for those with ALS involves approximately six onsite visits to MGH every three months for up to 18 months. Healthy volunteers are asked to make up to two onsite visits to MGH over the course of approximately two months. At these visits, participants will undergo an MRI scan to enable researchers to look at structural changes in the brain. Participants will also have blood drawn for analysis of inflammatory markers and generation of stem cells for further research. Other outcome assessments for ALS participants include breathing tests, muscle tests, and questionnaires, as well as an optional lumbar puncture to enable researchers to analyze biomarkers in the CSF. Finally, a subset of participants will undergo PET scans, which allow researchers to identify regions of inflammation in the brain.

Participants must be between the ages of 18 and 80, be medically safe to undergo an MRI scan (i.e., no metallic particles in the body), and be able to safely lie flat for at least 90 minutes. Additionally, participants cannot be taking any immunosuppressive medications or have a diaphragm pacing system and cannot have a diagnosis of Parkinson's disease, Alzheimer's disease, unstable psychiatric disease, cognitive impairment, or renal failure.

Principal Investigator: Nazem Atassi, MD, MMSc

Contact:
Beverly Reynolds
617-643-2522
bvreynolds@mgh.harvard.edu

GE-179

+Healthy Volunteers

This study is recruiting participants with Amyotrophic Lateral Sclerosis (ALS), as well as people without a history of neurological disease, using MRI and PET scans to look at the brain activity of certain receptors involved in neurotransmission. Criteria include, but are not limited to, the following:
1) Age 30 – 80
2) No electrically powered devices in their body
3) Able to lie flat comfortably for at least 90 minutes

The purpose of this research study is to determine whether there are differences between people with and without ALS in brain NMDA receptor activity (a channel present in nerve cells of brain and spinal cord that regulates neurotransmission). Participation in this study will involve up to 3 visits (a screening and one to two imaging sessions). The MRI and PET scans are compensated at $100 each and parking fees are waived.

Principal Investigator: Nazem Atassi, MD, MMSc

Contact:
Jianing Liu
617-726-1180
jliu45@mgh.harvard.edu